Vildagliptin / Metformin hydrochloride Accord

Country: European Union

Language: Latvian

Source: EMA (European Medicines Agency)

Active ingredient:

metformin hydrochloride, vildagliptin

Available from:

Accord Healthcare S.L.U.

ATC code:

A10BD08

INN (International Name):

vildagliptin / metformin hydrochloride

Therapeutic group:

Cukura diabēts

Therapeutic area:

Cukura diabēts, 2. tips

Therapeutic indications:

Vildagliptin/Metformin hydrochloride Accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).

Product summary:

Revision: 2

Authorization status:

Autorizēts

Authorization date:

2022-03-24

Patient Information leaflet

                                33
B. LIETOŠANAS INSTRUKCIJA
34
LIETOŠANAS INSTRUKCIJA: INFORMĀCIJA LIETOTĀJAM
VILDAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD 50 MG/850 MG APVALKOTĀS
TABLETES
VILDAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD 50 MG/1000 MG APVALKOTĀS
TABLETES
_vildagliptinum/metformini hydrochloridum_
PIRMS ZĀĻU LIETOŠANAS UZMANĪGI IZLASIET VISU INSTRUKCIJU, JO TĀ
SATUR JUMS SVARĪGU INFORMĀCIJU.
-
Saglabājiet šo instrukciju! Iespējams, ka vēlāk to vajadzēs
pārlasīt.
-
Ja Jums rodas jebkādi jautājumi, vaicājiet ārstam, farmaceitam vai
medmāsai.
-
Šīs zāles ir parakstītas tikai Jums. Nedodiet tās citiem. Tās
var nodarīt ļaunumu pat tad, ja šiem
cilvēkiem ir līdzīgas slimības pazīmes.
-
Ja Jums rodas jebkādas blakusparādības, konsultējieties ar ārstu
vai farmaceitu. Tas attiecas arī
uz iespējamām blakusparādībām, kas nav minētas šajā
instrukcijā. Skatīt 4. punktu.
ŠAJĀ INSTRUKCIJĀ VARAT UZZINĀT:
1.
Kas ir Vildagliptin/Metformin hydrochloride Accord un kādam nolūkam
to lieto
2.
Kas Jums jāzina pirms Vildagliptin/Metformin hydrochloride Accord
lietošanas
3.
Kā lietot Vildagliptin/Metformin hydrochloride Accord
4.
Iespējamās blakusparādības
5.
Kā uzglabāt Vildagliptin/Metformin hydrochloride Accord
6.
Iepakojuma saturs un cita informācija
1.
KAS IR VILDAGLIPTIN/METFORMIN HYDROCHLORIDE ACCORD UN KĀDAM NOLŪKAM
TO LIETO
Vildagliptin/Metformin hydrochloride Accord aktīvās vielas
vildagliptīns un metformīna hidrohlorīds
pieder pie zāļu grupas, ko sauc par iekšķīgi lietojamiem
pretdiabēta līdzekļiem.
Vildagliptin/Metformin hydrochloride Accord lieto, lai ārstētu
pieaugušos pacientus ar 2. tipa cukura
diabētu. Šo diabēta paveidu sauc arī par insulīnneatkarīgo
cukura diabētu. Vildagliptin/Metformin
hydrochloride Accord lieto, kad diabētu nevar kontrolēt tikai ar
diētu un fiziskām aktivitātēm un/vai
citām zālēm, kas paredzētas diabēta ārstēšanai (insulīnu vai
sulfonilurīnvielas atvasinājumiem).
2. tipa cukura diabēts rodas, kad organisms ne
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
I PIELIKUMS
ZĀĻU APRAKSTS
2
1.
ZĀĻU NOSAUKUMS
Vildagliptin/Metformin hydrochloride Accord 50 mg/850 mg apvalkotās
tabletes
Vildagliptin/Metformin hydrochloride Accord 50 mg/1000 mg apvalkotās
tabletes
2.
KVALITATĪVAIS UN KVANTITATĪVAIS SASTĀVS
Vildagliptin/Metformin hydrochloride Accord 50 mg/850 mg apvalkotās
tabletes
Katra apvalkotā tablete satur 50 mg vildagliptīna (
_vildagliptinum_
) un 850 mg metformīna hidrohlorīda
(
_metformini hydrochloridum_
) (atbilst 660 mg metformīna).
Vildagliptin/Metformin hydrochloride Accord 50 mg/1000 mg apvalkotās
tabletes
Katra apvalkotā tablete satur 50 mg vildagliptīna (
_vildagliptinum_
) un 1000 mg metformīna
hidrohlorīda (
_metformini hydrochloridum_
) (atbilst 780 mg metformīna).
Pilnu palīgvielu sarakstu skatīt 6.1. apakšpunktā.
3.
ZĀĻU FORMA
Apvalkotā tablete (tablete)
Vildagliptin/Metformin hydrochloride Accord 50 mg/850 mg apvalkotās
tabletes
Dzeltena, ovāla, abpusēji izliekta apvalkotā tablete, kurai vienā
pusē iespiests „GG2” un otra puse
gluda. Tabletes izmērs ir aptuveni 20,15 x 8,00 mm.
Vildagliptin/Metformin hydrochloride Accord 50 mg/1000 mg apvalkotās
tabletes
Tumši dzeltena, ovāla, abpusēji izliekta apvalkotā tablete, kurai
vienā pusē iespiests „GG3” un otra
puse gluda. Tabletes izmērs ir aptuveni 21,11 x 8,38 mm.
4.
KLĪNISKĀ INFORMĀCIJA
4.1.
TERAPEITISKĀS INDIKĀCIJAS
Vildagliptin/Metformin hydrochloride Accord ir indicēts papildus
diētai un fiziskajām aktivitātēm, lai
uzlabotu glikēmijas kontroli pieaugušiem pacientiem ar 2. tipa
cukura diabētu:
•
pacientiem, kuru stāvoklis netiek pietiekami kontrolēts tikai ar
metformīna hidrohlorīdu;
•
pacientiem, kuri ir jau ārstēti ar vildagliptīna un metformīna
hidrohlorīda kombināciju atsevišķu
tablešu veidā;
•
kombinācijā ar citām zālēm diabēta ārstēšanai, tai skaitā
insulīnu, ja tās nenodrošina pietiekamu
glikēmijas kontroli (skatīt 4.4., 4.5., un 5.1. apakšpunktu).
4.2.
DEVAS UN LIETOŠANAS VEIDS
Devas
_Pieaugušie
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 01-06-2023
Public Assessment Report Public Assessment Report Bulgarian 17-06-2022
Patient Information leaflet Patient Information leaflet Spanish 01-06-2023
Public Assessment Report Public Assessment Report Spanish 17-06-2022
Patient Information leaflet Patient Information leaflet Czech 01-06-2023
Public Assessment Report Public Assessment Report Czech 17-06-2022
Patient Information leaflet Patient Information leaflet Danish 01-06-2023
Public Assessment Report Public Assessment Report Danish 17-06-2022
Patient Information leaflet Patient Information leaflet German 01-06-2023
Public Assessment Report Public Assessment Report German 17-06-2022
Patient Information leaflet Patient Information leaflet Estonian 01-06-2023
Public Assessment Report Public Assessment Report Estonian 17-06-2022
Patient Information leaflet Patient Information leaflet Greek 01-06-2023
Public Assessment Report Public Assessment Report Greek 17-06-2022
Patient Information leaflet Patient Information leaflet English 01-06-2023
Public Assessment Report Public Assessment Report English 17-06-2022
Patient Information leaflet Patient Information leaflet French 01-06-2023
Public Assessment Report Public Assessment Report French 17-06-2022
Patient Information leaflet Patient Information leaflet Italian 01-06-2023
Public Assessment Report Public Assessment Report Italian 17-06-2022
Patient Information leaflet Patient Information leaflet Lithuanian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-06-2023
Public Assessment Report Public Assessment Report Lithuanian 17-06-2022
Patient Information leaflet Patient Information leaflet Hungarian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 01-06-2023
Public Assessment Report Public Assessment Report Hungarian 17-06-2022
Patient Information leaflet Patient Information leaflet Maltese 01-06-2023
Public Assessment Report Public Assessment Report Maltese 17-06-2022
Patient Information leaflet Patient Information leaflet Dutch 01-06-2023
Public Assessment Report Public Assessment Report Dutch 17-06-2022
Patient Information leaflet Patient Information leaflet Polish 01-06-2023
Public Assessment Report Public Assessment Report Polish 17-06-2022
Patient Information leaflet Patient Information leaflet Portuguese 01-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 01-06-2023
Public Assessment Report Public Assessment Report Portuguese 17-06-2022
Patient Information leaflet Patient Information leaflet Romanian 01-06-2023
Public Assessment Report Public Assessment Report Romanian 17-06-2022
Patient Information leaflet Patient Information leaflet Slovak 01-06-2023
Public Assessment Report Public Assessment Report Slovak 17-06-2022
Patient Information leaflet Patient Information leaflet Slovenian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 01-06-2023
Public Assessment Report Public Assessment Report Slovenian 17-06-2022
Patient Information leaflet Patient Information leaflet Finnish 01-06-2023
Public Assessment Report Public Assessment Report Finnish 17-06-2022
Patient Information leaflet Patient Information leaflet Swedish 01-06-2023
Public Assessment Report Public Assessment Report Swedish 17-06-2022
Patient Information leaflet Patient Information leaflet Norwegian 01-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 01-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 01-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 01-06-2023
Patient Information leaflet Patient Information leaflet Croatian 01-06-2023
Public Assessment Report Public Assessment Report Croatian 17-06-2022